

SHORT REPORT

Emergence of metallo- β -lactamase IMP-14 and VIM-2 in *Pseudomonas aeruginosa* clinical isolates from a tertiary-level hospital in Thailand

C. PIYAKUL¹, R. TIYAWISUTSRI² AND K. BOONBUMRUNG^{2*}

¹ Graduate Programme in Clinical Biochemistry and Molecular Medicine, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand

² Department of Transfusion Medicine, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand

(Accepted 10 June 2011; first published online 7 July 2011)

SUMMARY

Seventy-five clinical isolates of *Pseudomonas aeruginosa* collected in a tertiary teaching hospital in Thailand were investigated for susceptibility to antimicrobials including imipenem. Metallo- β -lactamase (MBL) enzymes were detected by E-test MBL assay and PCR; class 1 integron genes were also detected by PCR. Strains positive for *bla*_{IMP} and *bla*_{VIM} genes were further characterized by DNA sequencing and examined for clonality by pulsed-field gel electrophoresis. High rates of resistance to anti-pseudomonal agents were found. MBL enzymes were found in 13 (17.3%) strains and 24 (32%) carried class 1 integron genes. Twelve of the latter strains harboured the *bla*_{IMP-14} gene and one strain the *bla*_{VIM-2} gene. All of the IMP-14 strains were identical or closely related suggesting clonal dissemination of these genes.

Key words: Antibiotic resistance, *Pseudomonas*.

Pseudomonas aeruginosa producing metallo- β -lactamase (MBLs) have been recognized in several parts of the world, e.g. Poland, Southern Brazil, Taiwan, and Europe [1]. To date, at least 26 IMP and 30 VIM variants have been reported in several countries (<http://www.lahey.org/Studies/other.asptable1>). Genetic determinants of MBLs (*bla* genes) are mostly carried on class 1 and class 3 integrons [2] and can spread rapidly in hospitals via the integron system. In Thailand, Boonkerd *et al.* reported the first case of a *bla*_{IMP-1} gene in carbapenem-resistant *P. aeruginosa* in 2009; *bla*_{VIM}-type MBL was not found in their study [3]. We report here the prevalence of *bla*_{IMP} and *bla*_{VIM} genes associated with class 1 integrons and also investigated possible clonal

dissemination of *P. aeruginosa* by pulsed-field gel electrophoresis (PFGE) based on observations in a tertiary-level teaching hospital in Thailand during March–April 2009.

Non-duplicate, clinical isolates of *P. aeruginosa* were randomly selected and species identity was confirmed by standard techniques. Isolates were tested for susceptibility to 11 antimicrobial agents [amikacin (AMK), ceftazidime (CAZ), ciprofloxacin (CIP), colistin (CL), cefepime (FEP), gentamicin (GEN), imipenem (IPM), levofloxacin (LVX), meropenem (MEM), cefoperazone/sulbactam (SCFP) and piperacillin/tazobactam (TZP) (Oxoid, UK) by the disk diffusion assay according to Clinical and Laboratory Standards Institute (CLSI) guidelines [4]. Minimum inhibitory concentrations (MICs) of IPM were determined by an IPM E-test strip and isolates were screened for the presence of MBL enzymes by the E-test MBL strip (AB Biodisk, Sweden). A MIC

* Author for correspondence: K. Boonbumrung, Ph.D., Chulalongkorn University, 154 Chulapat 1, Ramal Road, Pathumwan, Bangkok 10330, Thailand.
(Email: khaemaporn.b@chula.ac.th)




Fig 1. Schematic representation of class 1 integron.

ratio (MIC of IPM alone/MIC of IPM plus EDTA) of ≥ 8 was interpreted as suggestive of MBL production. Genomic DNA of *P. aeruginosa* was extracted and purified by phenol/chloroform as described previously [5]. PCR amplification for MBL genes (*bla_{IMP}*, *bla_{VIM}*) was performed as described previously [6]. Class 1 integron genes were amplified by multiplex PCR with the following primers: *intI-1* primers (forward: 5'-GGC GCG CTG AAA GGT CTG GT-3'; reverse: 5'-CCG CTG CGT TCG GTC AAG GT-3'); *qacEΔ1* primers (forward: 5'-TTG CCC CTT CCG CCG TTG TC-3'; reverse: 5'-CCT CCG CAG CGA CTT CCA CG-3'); *sull* primers (forward: 5'-GAC GCG AGG CCT GTA TCG CC-3'; reverse: 5'-TCC GTC GCA AGG CGG AAA CC-3'). PCR products were purified and directly sequenced using IMP-F, IMP-R, VIM-F and VIM-R primers (1st BASE Pte Ltd, Thailand). DNA sequences were analysed by the BLAST program (<http://blast.ncbi.nlm.nih.gov/>). *P. aeruginosa* IMP-1-producing strains were kindly provided by Dr Neil Woodford as positive controls for MBL detection. Genotyping of isolates carrying *bla_{IMP}* or *bla_{VIM}* was performed by PFGE with the restriction enzyme *SpeI* in a CHEF Mapper system (Bio-Rad Laboratories, USA).

The 75 *P. aeruginosa* isolates were from sputum ($n=33$, 44%), urine ($n=21$, 28%), pus ($n=18$, 24%) and blood ($n=3$, 4%). Most isolates were resistant to LVX and CIP (54.7%), followed by CAZ (50.7%), SCFP (42.7%), TZP (42.7%), MEM (38.7%), and IPM (33.3%); all were susceptible to CL. Thirteen isolates (17.3%) were positive for MBLs by E-test and were multidrug resistant with a high-level of resistance to IPM (MIC >256 $\mu\text{g/ml}$). Thirteen isolates were also positive for the *bla_{IMP}* allele and one was positive for the *bla_{VIM}* allele. Nucleotide sequencing identified the *bla_{IMP}* and *bla_{VIM}* genes to be IMP-14 (GenBank EMBL accession no. GQ302617) and VIM-2 (accession no GQ853417). Twenty-four isolates (32.0%) were positive for class 1 integron genes (*intI-1*, *qacEΔ1*, *sull*; Fig. 1); 12 of these carried IMP-14, and one was VIM-2 positive. Another isolate with a *bla_{IMP}* gene was negative for class 1 integron genes. The *SpeI*-digested genomic DNA patterns of 14 isolates were classified into three types; A, B and C




Fig 2. Pulsed-field gel electrophoresis (PFGE) pattern of some of the *P. aeruginosa* isolates carrying MBL genes after digestion with *SpeI*. Lane M, lambda ladder (Promega, USA); lanes 1-14, isolates 20042, 20689, 20055, 20717, 60334, 60546, 20062, 60154, 20288, 60172, 20453, 20697, 20055, and 20832, respectively.

according to the criteria of Tenover *et al.* [7] (Fig. 2). Pattern A was dominant and consisted of five closely related restriction patterns for the 12 *bla_{IMP}*-producing isolates. The VIM-2 strain was unique (pattern C), and had a susceptibility profile identical with most strains of pattern A.

Corresponding with data from the National Antimicrobial Resistance Surveillance Center of Thailand, clinical isolates in the present study showed high rates of resistance to most anti-pseudomonal agents especially quinolones, β -lactam/inhibitor combinations, cephalosporins and carbapenems, but no resistance to CL was found underlining its potential as a reserve antibiotic for multidrug-resistant strains of *P. aeruginosa*.

As found in a previous study [8], integron-positive strains were significantly associated with resistance to aminoglycosides, quinolones, carbapenems and cephalosporins ($P \leq 0.001$). Interestingly, one strain carried the *bla_{IMP}* gene but not the integrase (*intI-1*)

gene and this raises the possibility of insertion of the *bla*_{IMP} gene into another class of integrons [2]. Moreover, two strains which were phenotypically positive for MBLs but negative for *bla*_{IMP} and other MBL-encoding genes (e.g. VIM-, GIM- and SPM-type), clearly produced MBL enzymes [9], one of which was identified as VIM-2 type. By contrast, two strains harboured the genes for *bla*_{IMP} and class 1 integrons but were negative by the MBL E-test. This was previously observed by Collis & Hall [10] who suggested that the expression of the cassette had been affected by the position of the antibiotic resistance gene cassette which was inserted in the region of the integron.

We have shown the emergence of *bla*_{IMP-14} and *bla*_{VIM-2} genes in MBL-producing *P. aeruginosa* strains. The IMP-14 MBL gene was first described in a *P. aeruginosa* clinical isolate from Thailand in 2004 (GenBank accession no. GQ302617, unpublished data), and the VIM-2-type MBL gene has been reported from many countries including Japan, South Korea, Portugal, Spain, and USA [11].

PFGE showed that all isolates in pattern A were from urine samples of patients from two wards suggesting that this was the predominant clone circulating in the hospital. Although seemingly related by DNA profile the remaining four strains with the IMP-14 gene originated from various specimens and wards. Thus MBL-producing strains exhibited both clonality and diversity, which underlines that their prevalence cannot be explained solely by clonal expansion of a particular strain type.

In Thailand, the prevalence of MBL (*bla*_{IMP} and *bla*_{VIM})-producing *P. aeruginosa* strains associated with class 1 integrons has not yet been investigated in a large-scale study. Our preliminary survey showed that 17.3% of *P. aeruginosa* strains isolated over 2 months tested positive for MBL-producing genes. These data underline the importance of the emergence of MBLs associated with class 1 integrons and highlight the need for the development of infection control strategies in order to combat the spread of multidrug-resistant strains in hospitals by more efficient and appropriate prescribing of selected reserve drugs such as the carbapenems.

ACKNOWLEDGEMENTS

This study was financially supported by a Graduate thesis grant, Graduate School, Chulalongkorn University, and Chulalongkorn University Centenary Academic Development Project. Cherman Piyakul

received a graduate tuition fee scholarship and teaching assistant fellowship from the Faculty of Allied Health Sciences, Chulalongkorn University. The authors thank Mr Somsak Rahul for providing *P. aeruginosa* clinical isolates.

DECLARATION OF INTEREST

None.

REFERENCES

1. **Livermore DM.** Multiple mechanisms of antimicrobial resistance in *Pseudomonas aeruginosa*: our worst nightmare? *Clinical Infectious Diseases* 2002; **34**: 634–640.
2. **Shibata N, et al.** PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. *Journal of Clinical Microbiology* 2003; **41**: 5407–5413.
3. **Boonkerd N, et al.** Class 1 integron containing metallo beta-lactamase gene *bla*_{IMP-1} in carbapenem-resistant *Pseudomonas aeruginosa* in Thailand. *Journal of Infection and Chemotherapy* 2009; **15**: 257–261.
4. **Clinical and Laboratory Standards Institute.** Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA, CLSI, 2009.
5. **Goldberg JB, Ohman DE.** Cloning and expression in *Pseudomonas aeruginosa* of a gene involved in the production of alginate. *Journal of Bacteriology* 1984; **158**: 1115–1121.
6. **Ellington MJ, et al.** Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. *Journal of Antimicrobial Chemotherapy* 2007; **59**: 321–322.
7. **Tenover FC, et al.** Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *Journal of Clinical Microbiology* 1995; **33**: 2233–2239.
8. **Gu B, et al.** Prevalence and characterization of class I integrons among *Pseudomonas aeruginosa* and *Acinetobacter baumannii* isolates from patients in Nanjing, China. *Journal of Clinical Microbiology* 2007; **45**: 241–243.
9. **Lee MF, et al.** Molecular characterisation of the metallo-beta-lactamase genes in imipenem-resistant Gram-negative bacteria from a university hospital in southern Taiwan. *International Journal of Antimicrobial Agents* 2008; **32**: 475–480.
10. **Collis CM, Hall RM.** Expression of antibiotic resistance genes in the integrated cassettes of integrons. *Antimicrobial Agents and Chemotherapy* 1995; **39**: 155–162.
11. **Walsh TR, et al.** Metallo-beta-lactamases: the quiet before the storm? *Clinical Microbiology Reviews* 2005; **18**: 306–325.